Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study

The objective of this study was to evaluate the safety and tolerability of DS-1205c, an oral AXL-receptor inhibitor, in combination with osimertinib in metastatic or unresectable EFGR-mutant non-small cell lung cancer (NSCLC) patients who developed disease progression during EGFR tyrosine kinase inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, James Chih-Hsin, Su, Wu-Chou, Chiu, Chao-Hua, Shiah, Her-Shyong, Lee, Kang-Yun, Hsia, Te-Chun, Uno, Makiko, Crawford, Nigel, Terakawa, Hiroshi, Chen, Wen-Chi, Takayama, Gensuke, Hsu, Ching, Hong, Ying, Saintilien, Carline, McGill, Joseph, Chang, Gee-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140009/
https://www.ncbi.nlm.nih.gov/pubmed/36892745
http://dx.doi.org/10.1007/s10637-023-01341-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140009/
https://www.ncbi.nlm.nih.gov/pubmed/36892745
http://dx.doi.org/10.1007/s10637-023-01341-y

Ejemplares similares